The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-29. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== E3 subunit === The E3 component is a flavoprotein, and it re-oxidizes the reduced lipoyl sulfur residues of E2 using FAD (a catalytic cofactor) as the oxidant. FAD then transfers these protons and electrons to NAD+ (a stoichiometric cofactor) to complete the reaction cycle.
== Achievements == Lee is best known for his research in capillary separations and mass spectrometry detection. He is an author or co-author of over 550 scientific publications. Among the scientific awards that he has received for his achievements in research and professional activities are the M.S. Tswett Chromatography Medal (1984), the Keene P. Dimick Chromatography Award (1988), the American Chemical Society Award in Chromatography (1988), the Russian Tswett Chromatography Medal (1992), the Martin Gold Medal (1996), the Latin-American Chromatography Congress Medal (1998), the M.J.E. Golay Award (1998), the American Chemical Society Award in Chemical Instrumentation (1998), an honorary doctorate from Uppsala University in Sweden (1998), the Dal Nogare Award (1999), the Eastern Analytical Symposium Award for Achievements in Separation Science (1999), the California Separation Science Society Award (2005), the Pittsburgh Analytical Chemistry Award (2008), R&D 100 Awards (1993, 2008), Eastern Analytical Symposium Award for Outstanding Achievements in the Fields of Analytical Chemistry (2008), the American Chemical Society Award in Separations Science and Technology (2012), and the LC/GC Europe Lifetime Achievement Award (2014). He is also an entrepreneur and has been involved in transferring technology from his university research laboratory to the private sector.
== Side effects == Adverse events are generally caused by incorrect dosing. Long-term suppression of TSH values below normal values frequently causes cardiac side effects and contributes to decreases in bone mineral density (low TSH levels are also well known to contribute to osteoporosis). Too high a dose of levothyroxine causes hyperthyroidism. Overdose can result in heart palpitations, abdominal pain, nausea, anxiety, confusion, agitation, insomnia, weight loss, and increased appetite. Acute massive overdose may be life-threatening; treatment should be symptomatic and supportive. Massive overdose can be associated with increased sympathetic activity, thus may require treatment with beta blockers. The effects of overdosing appear 6 hours to 11 days after ingestion.
The war on drugs, sometimes referred to in the 21st century as the war on cartels in contexts of military intervention and counterterrorism, is a global anti-narcotics campaign led by the United States federal government, ramped up after 9/11, including drug prohibition and foreign assistance, with the aim of reducing the illegal drug trade in the US. The initiative's efforts includes policies intended to discourage the production, distribution, and consumption of psychoactive drugs that the participating governments, through United Nations treaties, have made illegal. The term "war on drugs" was popularized by the media after a press conference, given on June 17, 1971, during which President Richard Nixon declared drug abuse "public enemy number one". Earlier that day, Nixon had presented a special message to the US Congress on "Drug Abuse Prevention and Control", which included text about devoting more federal resources to the "prevention of new addicts, and the rehabilitation of those who are addicted"; that aspect did not receive the same media attention as the term "war on drugs". In the years since, presidential administrations and Congress have generally maintained or expanded Nixon's original initiatives, with the emphasis on law enforcement and interdiction over public health and treatment. Cannabis presents a special case; it came under federal restriction in the 1930s, and since 1970 has been classified as having a high potential for abuse and no medical value, with the same level of prohibition as heroin.
Sources: en.wikipedia.org
The total period of time beginning with the date of manufacture, date of cure (for elastomeric and rubber products only), date of assembly, or date of pack (subsistence only), and terminated by the date by which an item must be used (expiration date) or subjected to inspection, test, restoration, or disposal action; or after inspection/laboratory test/restorative action that an item may remain in the combined wholesale (including manufacture's) and retail storage systems and still be suitable for issue or use by the end user. Shelf-life is not to be confused with service-life (defined as, A general term used to quantify the average or standard life expectancy of an item or equipment while in use. When a shelf-life item is unpacked and introduced to mission requirements, installed into intended application, or merely left in storage, placed in pre-expended bins, or held as bench stock, shelf-life management stops and service life begins.)
Machaca – a dish prepared most commonly from dried, spiced beef or pork, then rehydrated and pounded to make it tender. The reconstituted meat would then be used to prepare any number of dishes. Meat extract – highly concentrated meat stock, usually made from beef. It is used to add meat flavor in cooking, and to make broth for drinking. Meat extracts have largely been supplanted by bouillon cubes and yeast extract.
A Border checkpoint is a place where goods or individuals moving across borders are inspected for compliance with border control measures. Access-controlled borders often have a limited number of checkpoints where they can be crossed without legal sanctions. Arrangements or treaties may be established to allow or mandate less-restrained crossings (e.g., the Schengen Agreement). Land border checkpoints (land ports of entry) can be contrasted with the customs and immigration facilities at seaports, international airports, and other ports of entry. Checkpoints generally serve two purposes:
Sources: en.wikipedia.org
It probably happens because the digestive system senses and signals forthcoming delivery of sugars, inhibiting fatty acid release and oxidation, and starving glycogen-less muscle cells of the sole available source of energy. Even simple continuous exercise, like walking or washing dishes by hand right after the meal, may trigger rhabdomyolysis in the exercising muscles. This rhabdomyolysis is probably not of exertional, but of hypoglycemic nature, as loaded glycogen-less muscles can rapidly remove glucose from blood, and the normal mechanism of glucose homeostasis lacks the required responsiveness or capacity to prevent hypoglycemia. The broken down myocytes probably do not yield much glucose. Unlike the case with exertional rhabdomyolysis, there is no warning. At rest, however, the liver will effortlessly cover the whole body energy needs until absorption of carbohydrates occurs. If a large group of muscles is still actively drawing fuels from blood after the most recent continuous exercise, in order to replenish the ATP and the phosphocreatine reserve, it may become sour without any additional exercise by the time the carbohydrate meal is finished. If the carbohydrate meal consists of a food (which doesn't need to be carbohydrate itself), that requires prolonged vigorous chewing, and then some time to be digested, for instance parboiled long grain rice, chewing may suddenly become very slow and difficult halfway through the meal.
==== Declined ==== Jasmine Crockett, incumbent U.S. representative (ran for U.S. Senate) Domingo García, former president of the League of United Latin American Citizens (2018–2024) and candidate for this district in 2012 Marc Veasey, incumbent U.S. representative from the 25th district (ran for Tarrant County judge)
The urinary system consists of the two kidneys, two ureters, bladder, and urethra. It removes waste materials from the blood through urine, which carries a variety of waste molecules and excess ions and water out of the body. First, the kidneys filter the blood through their respective nephrons, removing waste products like urea, creatinine and maintaining the proper balance of electrolytes and turning the waste products into urine by combining them with water from the blood. The kidneys filter about 150 quarts (170 liters) of blood daily, but most of it is returned to the blood stream with only 1-2 quarts (1-2 liters) ending up as urine, which passes from the kidneys through the ureters into the bladder. The smooth muscles lining the ureter walls continuously tighten and relax through a process called peristalsis, forcing small amounts of urine into the bladder every 10–15 seconds. The bladder is a hollow balloon shaped organ located in the pelvis. It stores urine until the brain signals it to relax the urinary sphincter and release the urine into the urethra starting urination. A normal bladder can hold up to 16 ounces (half a liter) for 3–5 hours comfortably. Numerous diseases affect the urinary system including kidney stones, which are formed when materials in the urine concentrate enough to form a solid mass, urinary tract infections, which are infections of the urinary tract and can cause pain when urinating, frequent urination and even death if left untreated.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.